Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):482–488. doi: 10.1054/bjoc.2000.1627

Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons

S Pages 1, V Caux 1, D Stoppa-Lyonnet 1, M Tosi 2,3
PMCID: PMC2363770  PMID: 11207042

Abstract

41 breast cancer or breast-ovarian cancer families, including 12 families with at least one affected first-degree male relative, were screened for mutations in the BRCA2 gene. Mutations had not been found in the BRCA1 gene of these families. Chemical cleavage of Mismatch was used to identify nucleotide changes within large PCR products (average size 1.2 kb) that carried strand-specific fluorescent end-labels. 15 amplicons were sufficient to scan 18 exons, including the large exon 11. The remaining 9 small exons were examined by Denaturing Gradient Gel Electrophoresis. The high sensitivity of this approach was documented by the detection, in these 41 patients, of all 9 exonic single nucleotide polymorphisms reported with heterozygosity >0.1. Truncating BRCA2 mutations were found in 7 of the 41 families. 3 of them were in the group of 12 families comprising cases of male breast cancer. Since the methods used here have no bias for particular types of mutations, these data confirm the high proportion of frameshifts among mutations in BRCA2. However, relevant single nucleotide substitutions were also found: one resulting in a stop codon and another one, present in a male patient, was the previously reported change Asp2723His, that affects a highly conserved region of the BRCA2 protein. This study indicates a BRCA2 contribution of 10% (95% CI 2.5–17.5) to our original cohort of 59 breast-ovarian cancer families, whereas the contribution of BRCA1 had been estimated at 46% (95% CI 33–59). © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: male breast cancer, breast-ovarian cancer, FAMA, chemical cleavage of mismatch, chimeric PCR primers

Full Text

The Full Text of this article is available as a PDF (159.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Connor F., Smith A., Wooster R., Stratton M., Dixon A., Campbell E., Tait T. M., Freeman T., Ashworth A. Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. Hum Mol Genet. 1997 Feb;6(2):291–300. doi: 10.1093/hmg/6.2.291. [DOI] [PubMed] [Google Scholar]
  2. Easton D. F., Bishop D. T., Ford D., Crockford G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993 Apr;52(4):678–701. [PMC free article] [PubMed] [Google Scholar]
  3. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997 Jan;15(1):103–105. doi: 10.1038/ng0197-103. [DOI] [PubMed] [Google Scholar]
  5. Griffais R., André P. M., Thibon M. K-tuple frequency in the human genome and polymerase chain reaction. Nucleic Acids Res. 1991 Jul 25;19(14):3887–3891. doi: 10.1093/nar/19.14.3887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Marston N. J., Richards W. J., Hughes D., Bertwistle D., Marshall C. J., Ashworth A. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol. 1999 Jul;19(7):4633–4642. doi: 10.1128/mcb.19.7.4633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. McAllister K. A., Haugen-Strano A., Hagevik S., Brownlee H. A., Collins N. K., Futreal P. A., Bennett L. M., Wiseman R. W. Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene. Cancer Res. 1997 Aug 1;57(15):3121–3125. [PubMed] [Google Scholar]
  8. Rahman N., Stratton M. R. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95–121. doi: 10.1146/annurev.genet.32.1.95. [DOI] [PubMed] [Google Scholar]
  9. Sharan S. K., Bradley A. Murine Brca2: sequence, map position, and expression pattern. Genomics. 1997 Mar 1;40(2):234–241. doi: 10.1006/geno.1996.4573. [DOI] [PubMed] [Google Scholar]
  10. Stoppa-Lyonnet D., Laurent-Puig P., Essioux L., Pagès S., Ithier G., Ligot L., Fourquet A., Salmon R. J., Clough K. B., Pouillart P. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet. 1997 May;60(5):1021–1030. [PMC free article] [PubMed] [Google Scholar]
  11. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337. doi: 10.1038/ng0396-333. [DOI] [PubMed] [Google Scholar]
  12. Unger M. A., Nathanson K. L., Calzone K., Antin-Ozerkis D., Shih H. A., Martin A. M., Lenoir G. M., Mazoyer S., Weber B. L. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000 Sep 7;67(4):841–850. doi: 10.1086/303076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Verpy E., Biasotto M., Brai M., Misiano G., Meo T., Tosi M. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am J Hum Genet. 1996 Aug;59(2):308–319. [PMC free article] [PubMed] [Google Scholar]
  14. Verpy E., Biasotto M., Meo T., Tosi M. Efficient detection of point mutations on color-coded strands of target DNA. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1873–1877. doi: 10.1073/pnas.91.5.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wagner T. M., Hirtenlehner K., Shen P., Moeslinger R., Muhr D., Fleischmann E., Concin H., Doeller W., Haid A., Lang A. H. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999 Mar;8(3):413–423. doi: 10.1093/hmg/8.3.413. [DOI] [PubMed] [Google Scholar]
  16. Welcsh P. L., Owens K. N., King M. C. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000 Feb;16(2):69–74. doi: 10.1016/s0168-9525(99)01930-7. [DOI] [PubMed] [Google Scholar]
  17. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES